NZ506893A - Paroxetine compositions adsorbed or absorbed by a solid carrier - Google Patents

Paroxetine compositions adsorbed or absorbed by a solid carrier

Info

Publication number
NZ506893A
NZ506893A NZ506893A NZ50689399A NZ506893A NZ 506893 A NZ506893 A NZ 506893A NZ 506893 A NZ506893 A NZ 506893A NZ 50689399 A NZ50689399 A NZ 50689399A NZ 506893 A NZ506893 A NZ 506893A
Authority
NZ
New Zealand
Prior art keywords
absorbed
paroxetine
solid carrier
adsorbed
pharmaceutically acceptable
Prior art date
Application number
NZ506893A
Inventor
Andrew Simon Craig
Neal Ward
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NZ506893A publication Critical patent/NZ506893A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Paroxetine or a pharmaceutically acceptable derivative thereof adsorbed on or absorbed by a pharmaceutically acceptable solid carrier, and the use of the composition as a therapeutic agent or for the manufacture of a medicament is disclosed. Therapeutic uses of the paroxetine product disclosed herein include treatment of alcoholism, anxiety, depression, obsessive compulsive disorder, panic disorder, chronic pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia, pre-menstrual syndrome (PMS), adolescent depression, trichotillomania, dysthymia, and substance abuse.
NZ506893A 1998-03-24 1999-03-24 Paroxetine compositions adsorbed or absorbed by a solid carrier NZ506893A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9806312.6A GB9806312D0 (en) 1998-03-24 1998-03-24 Novel formulations
PCT/GB1999/000922 WO1999048499A1 (en) 1998-03-24 1999-03-24 Paroxetine compositions

Publications (1)

Publication Number Publication Date
NZ506893A true NZ506893A (en) 2003-06-30

Family

ID=10829181

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ506893A NZ506893A (en) 1998-03-24 1999-03-24 Paroxetine compositions adsorbed or absorbed by a solid carrier

Country Status (20)

Country Link
EP (1) EP1063993A1 (en)
JP (1) JP2002507569A (en)
CN (1) CN1125639C (en)
AP (1) AP2000001914A0 (en)
AU (1) AU754765B2 (en)
BG (1) BG104865A (en)
BR (1) BR9908991A (en)
CA (1) CA2324612A1 (en)
EA (1) EA003393B1 (en)
GB (1) GB9806312D0 (en)
HU (1) HUP0101326A3 (en)
ID (1) ID26485A (en)
IL (1) IL138478A0 (en)
NO (1) NO313404B1 (en)
NZ (1) NZ506893A (en)
PL (1) PL343095A1 (en)
SK (1) SK14102000A3 (en)
TR (1) TR200002750T2 (en)
WO (1) WO1999048499A1 (en)
ZA (1) ZA200005697B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914600D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel,process
DK200100341A (en) * 2001-03-02 2002-09-03 Gea Farmaceutisk Fabrik As Process for the preparation of pharmaceutical tablets containing paroxetine hydrochloride anhydrate
EP1643975A2 (en) * 2003-07-02 2006-04-12 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
US8062664B2 (en) 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
HU1000278D0 (en) * 2010-05-28 2010-07-28 Egis Gyogyszergyar Nyilvanosan Novel pharmaceutical use uf silicic acid
CN103961333B (en) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 Paroxetine mesylate capsule and preparation method thereof
CN104027306A (en) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 Paroxetine oral suspension and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
ES2058061T3 (en) * 1985-10-25 1994-11-01 Beecham Group Plc DERIVED FROM PIPERIDINE, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT.
AR001982A1 (en) * 1995-02-06 1998-01-07 Smithkline Beecham Plc PAROXETINE CHLORHYDRATE ANHYDRATED, AND PROCEDURE FOR ITS PREPARATION
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride

Also Published As

Publication number Publication date
AU754765B2 (en) 2002-11-21
EP1063993A1 (en) 2001-01-03
NO313404B1 (en) 2002-09-30
IL138478A0 (en) 2001-10-31
CA2324612A1 (en) 1999-09-30
AU3045199A (en) 1999-10-18
BG104865A (en) 2001-05-31
TR200002750T2 (en) 2000-12-21
ID26485A (en) 2001-01-11
CN1125639C (en) 2003-10-29
WO1999048499A1 (en) 1999-09-30
NO20004740L (en) 2000-10-03
HUP0101326A2 (en) 2002-05-29
JP2002507569A (en) 2002-03-12
SK14102000A3 (en) 2001-03-12
PL343095A1 (en) 2001-07-30
BR9908991A (en) 2000-12-12
EA200000977A1 (en) 2001-02-26
AP2000001914A0 (en) 2000-09-30
CN1294512A (en) 2001-05-09
HUP0101326A3 (en) 2002-06-28
EA003393B1 (en) 2003-04-24
ZA200005697B (en) 2001-10-02
GB9806312D0 (en) 1998-05-20
NO20004740D0 (en) 2000-09-22

Similar Documents

Publication Publication Date Title
UA49796C2 (en) paroxetine hydrochloride anhydrate, method for preparing the above, paroxetine hydrochloride, method of preparing the above, method of treating and/or diseases preventing and pharmaceutical composition
WO2003045918A8 (en) Piperidine-based mch antagonists for treatment of obesity and cns disorders
WO2004009015A3 (en) Combination therapy for the treatment of obesity
MXPA05003629A (en) Novel alkyne compounds having an mch antagonistic effect and medicaments containing these compounds.
MXPA04001850A (en) Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators.
YU85303A (en) The use of enantiomeric pure escitalopram
NZ506893A (en) Paroxetine compositions adsorbed or absorbed by a solid carrier
HRP20080262T3 (en) 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
PL373622A1 (en) Spirocyclic piperidines as mch1 antagonists and uses thereof
DE69026881D1 (en) 4-Substituted 17-beta (cyclopropylamino) androst-5-en-3-beta-ol and its derivatives, usable as inhibitors of C17-20 lyase
BR0208040A (en) Substituted benzofuran-2-carboxamide derivatives
IL148084A0 (en) Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans
IL158828A0 (en) Novel heteroaryl derivatives, their preparation and use
CA2288533A1 (en) New 4-substituted piperidines
HUP0003074A2 (en) Pharmaceutical composition comprising ssri and betha-blocking agent
BR0209342A (en) Azaheterocyclylmethyl antidepressants derived from 2,3 dihydro-1,4-dioxino [2,3-f] quinoxaline; method of treatment using such compounds; process to prepare them
MXPA05010678A (en) 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors.
MY123686A (en) Indole derivatives and their use as 5ht2a ligands
UA81469C2 (en) 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
AU3360000A (en) Use of 4-amino pyridine for treatment of peripheral neuropathies
MXPA03011766A (en) Novel indole derivatives.
WO2004035574A3 (en) Substituted aminoquinuclidine compounds and their use as delta-opioid receptor ligands
DE50006244D1 (en) Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
NZ514768A (en) 4-phenylpiperidine (such as paroxetine) alkane or phenyl sulphonate derivatives useful for treating pain
CA2521030A1 (en) 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed